AIDS Vaccine Report Calls for Full Research Funding
May 19, 2009
The new 13th annual AIDS Vaccine Advocacy Coalition (AVAC) report says the vaccine field is energized by "discovery, innovation, and basic science," and it warns against cuts during the current economic downturn.
Warren cited as an example a novel way researchers recently produced antibodies through gene-transfer, instead of relying on the body's immune system. "It doesn't mean we have an AIDS vaccine, but it means we have an entirely new approach to trying to deliver protection," he said.
Another reason for optimism is that useful information was yielded from the failed STEP trials involving Merck and Co.'s AIDS vaccine candidate, according to AVAC's report. "A study that showed a product didn't work is actually providing us an unimaginable amount of information," Warren said.
In this economic environment, "I believe that every dollar spent is going to be held up to a greater scrutiny, as budgets tighten and as funders have to re-examine their priorities," Warren said. But the vaccine hunt could cost even more later if scientific research is not fully funded now, he said.
Voice of America News
05.18.2009; Joe DeCapua
This article was provided by U.S. Centers for Disease Control and Prevention. It is a part of the publication CDC HIV/Hepatitis/STD/TB Prevention News Update. Visit the CDC's website to find out more about their activities, publications and services.